Now showing items 1-4 of 4

Corticobasal syndrome as a focal variant of Alzheimer’s disease

Mariani, Francesca; Damian, Andrés; Duarte, Pablo; Pino, Stephanie; Dansilio, Sergio; Ferrando, Rodolfo (Corporación Universidad de la CostaColombia, 2022-12-11)

Presentamos el caso de una mujer de 60 años, con un déficit progresivo de memoria anterógrada de 2 años de evolución. Se realizó estudios 18F-FDG PET/C y 11C-PIB PET/CT compatibles con EA. En la evolución presentó un ...
Corticobasal syndrome as a focal variant of Alzheimer’s disease

Mariani, Francesca; Damian, Andrés; Duarte, Pablo; Pino, Stephanie; Dansilio, Sergio; Ferrando, Rodolfo (Corporación Universidad de la CostaColombia, 2022)

We present a 60-year-old woman with a 2-year history of progressive anterograde memory deficit, that evolved with a typical corticobasal syndrome with extrapyramidal signs and left superior limb dystonia. 18F-FDG and 11C-PIB ...
Memory recovery through gene therapy with a single chain antibody fragment selective for Aβ oligomers in a model of Alzheimer’s disease in rats

Colettis, Natalia; Oberholzer, Maria Victoria; Cercato, Magali; Habif, Martin; Selles, Maria Clara; Salas, Daniela; Sebollela, Adriano; Klein, William-L.; Epstein, Alberto; Salvetti, Anna; Ferreira, Sergio-T.; Jerusalinsky, Diana (Corporación Universidad de la CostaColombia, 2023)

Strong evidence supports the hypothesis that synapse damage and memory impairment in early Alzheimer disease (AD) might be due to synaptic failure caused by amyloid beta oligomers (AβOs). We demonstrated the preclinical ...
Utility of a screening test (MoCa) to predict amyloid physiopathology in mild cognitive impairment

Clarens, María Florencia; Calandri, Ismael Luis; Helou, Maria Belen; Martín, María-Eugenia; Chrem Mendez, Patricio; Crivelli, Lucia (Corporación Universidad de la CostaColombia, 2020-12-09)

Introduction: The MoCa (Montreal Cognitive Assessment) Screening test has become relevant in recent years in the screening of patients with Mild Cognitive Impairment (MCI). It is important to seek and study simple and ...

Envíos recientes

Corticobasal syndrome as a focal variant of Alzheimer’s disease
...
Mariani, Francesca | 2022-12-11

Presentamos el caso de una mujer de 60 años, con un déficit progresivo de memoria anterógrada de 2 años de evolución. Se realizó estudios 18F-FDG PET/C y 11C-PIB PET/CT compatibles con EA. En la evolución presentó un síndrome cortico basal típico, con signos extrapiramidales y distonia de miembro superior izquierdo. Tanto los hallazgos de imagen, como la presentación clínica son consistentes con una presentación focal de EA

LEER
Corticobasal syndrome as a focal variant of Alzheimer’s disease
...
Mariani, Francesca | 2022

We present a 60-year-old woman with a 2-year history of progressive anterograde memory deficit, that evolved with a typical corticobasal syndrome with extrapyramidal signs and left superior limb dystonia. 18F-FDG and 11C-PIB PET/CT studies supported the diagnosis of Alzheimer’s disease associating a corticobasal syndrome.

LEER
Memory recovery through gene therapy with a single chain antibody fragment selective for Aβ oligomers in a model of Alzheimer’s disease in rats
...
Colettis, Natalia | 2023

Strong evidence supports the hypothesis that synapse damage and memory impairment in early Alzheimer disease (AD) might be due to synaptic failure caused by amyloid beta oligomers (AβOs). We demonstrated the preclinical efficacy of a single-chain variable-fragment (scFv) antibody NUsc1 that selectively targets a subpopulation of AβOs; NUsc1 prevented AβO-induced inhibition of long-term potentiation in hippocampal slices and short-term memory impairment in mice. Since specific targeting of AβOs by NUsc1 may be a substantial improvement in target engagement and efficacy for AD therapy, we developed an adeno-associated virus (AAV) vector to drive neuronal expression of NUsc1 within the brain. AAV-NUsc1 rescued short-term memory (STM) for objects and congeners interaction in mice AD models. Purpose: In heterozygous McGill-R-Thy1-APP transgenic (Tg+/–) rat model of AD, progressive amyloid pathology is accompanied by cognitive impairment involving long-term memory (LTM) decline. LTM in a novel-object-recognition (NOR) task was impaired in 4-month-old (Tg+/–) male rats, suggesting that they are unable to form/evoke such discriminative memories. Hence, we investigated if AAV-NUsc1 treatment could rescued this memory. Methods: 10-12 weeks-old either Tg or wild type male rats were i.c.v. infused with AAV-NUsc1. Two months later, short-term exploratory behavior, habituation to an open field (OF), object discrimination and LTM for objects were assessed. Results: AAV-NUsc1 treated Tg rats were able to successfully perform the task 24 h after training, denoting recovery of LT discrimination capacity and LTM formation. Wild type rats successfully performed the task either treated or not with AAV-NUsc1. Also, exploration and short-term habituation to an open field was preserved in Tg+/– rats either treated or not. Conclusions: Our present and previous results suggest that AAV-NUsc1 represents a significant advance in gene therapy, supporting the feasibility of immunotherapy using viral vector-mediated NUsc1 gene delivery as a potential therapeutic approach in AD.

LEER
Utility of a screening test (MoCa) to predict amyloid physiopathology in mild cognitive impairment
...
Clarens, María Florencia | 2020-12-09

Introduction: The MoCa (Montreal Cognitive Assessment) Screening test has become relevant in recent years in the screening of patients with Mild Cognitive Impairment (MCI). It is important to seek and study simple and reliable tools in clinical practices that correlate with biological markers that have been used to predict conversion from MCI to AD. Objective: To analyze the MOCA and its cognitive sub-scores and the relationship with Amyloid pathophysiology in Alzheimer’s Disease. Methodology: 32 patients with MCI were studied, they were separated according positive (n: 20) and negative (n: 12) underlying amyloid pathology. The patients performed a extensive cognitive assessment that included MoCa Test. Results: MoCa Total Scores showed significantly different results between groups (p < 0.001) and the Orientation Score (MoCa OIS)) (p < 0.05) with worse performance of patients with amyloid pathophysiology. Score of MoCa a cut-off point of < 24 was established, since the diagnostic sensitivity at this point was 83% and the specificity 70%. Conclusions: The MoCa is a useful tool to differentiate biomarker status in MCI. Future studies should study this tool in the prodromal phases of the disease.

LEER

Browsing by Subject "Enfermedad de Alzheimer"

Corticobasal syndrome as a focal variant of Alzheimer’s disease ﻿

Corticobasal syndrome as a focal variant of Alzheimer’s disease ﻿

Memory recovery through gene therapy with a single chain antibody fragment selective for Aβ oligomers in a model of Alzheimer’s disease in rats ﻿

Utility of a screening test (MoCa) to predict amyloid physiopathology in mild cognitive impairment ﻿

Envíos recientes

Corticobasal syndrome as a focal variant of Alzheimer’s disease

Corticobasal syndrome as a focal variant of Alzheimer’s disease

Memory recovery through gene therapy with a single chain antibody fragment selective for Aβ oligomers in a model of Alzheimer’s disease in rats

Utility of a screening test (MoCa) to predict amyloid physiopathology in mild cognitive impairment

Corticobasal syndrome as a focal variant of Alzheimer’s disease

Corticobasal syndrome as a focal variant of Alzheimer’s disease

Memory recovery through gene therapy with a single chain antibody fragment selective for Aβ oligomers in a model of Alzheimer’s disease in rats

Utility of a screening test (MoCa) to predict amyloid physiopathology in mild cognitive impairment